大疱性类天疱疮:现代诊疗实用方法
大疱性类天疱疮(BP)是最常见的自身免疫性表皮下大疱性疾病,主要表现为张力性大疱和剧烈瘙痒。本文简要讨论其临床表型、诊断基础及近期实验室进展,并综述包括生物制剂和JAK抑制剂在内的新兴治疗选择,强调个体化医疗和改善患者结局。
要点
- BP诊断需结合临床表现与实验室检查,新进展提高了诊断敏感性和准确性。
- 治疗格局已演变,生物制剂和JAK抑制剂可靶向免疫发病机制。
- 新兴疗法可能减少累积糖皮质激素和传统免疫抑制剂的副作用。
核心结论
- BP诊疗需综合临床表型、诊断基础和实验室进展,新兴靶向治疗有望改善患者结局。
研究设计与样本
- 本文为综述,简要讨论BP表型、诊断基础和实验室进展,并总结新兴治疗选择。
主要发现
- BP主要表现为张力性大疱和剧烈瘙痒,临床 presentations 多变。
- 近期实验室进展提高了诊断敏感性和准确性。
- 利妥昔单抗、奥马珠单抗、度普利尤单抗和JAK抑制剂等靶向免疫发病机制。
临床怎么用
- 临床应认识BP的多种表型,结合实验室进展进行诊断。
- 治疗可考虑新兴靶向疗法以减少糖皮质激素和传统免疫抑制剂累积暴露。
- 强调个体化医疗以改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, primarily presenting with tense bullae and severe pruritus. Diagnosing and treating BP can be challenging due to its variable clinical presentations. We will briefly discuss these phenotypes, highlight diagnostic basics, and briefly summarize recent laboratory advancements that have improved diagnostic sensitivity and accuracy. The treatment landscape for BP has evolved significantly. Newer therapies, including biologics such as rituximab, omalizumab, dupilumab, and Janus kinase inhibitors target the immunopathogenesis of BP and can reduce the adverse effects associated with cumulative corticosteroid exposure and conventional immunosuppressants. This article provides a comprehensive overview of BP's clinical features, diagnostic approaches, and emerging therapeutic options, emphasizing personalized medicine, and improved patient outcomes.
引用
- Powers CM, Thakker S, Gulati N, et al. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era. J Am Acad Dermatol. 2025. PMID: 39914667. doi:10.1016/j.jaad.2025.01.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。